Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Receivables (2016 - 2025)

Sangamo Therapeutics has reported Change in Receivables over the past 16 years, most recently at -$152000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$152000.0 for Q4 2025, up 98.48% from a year ago — trailing twelve months through Dec 2025 was -$155000.0 (up 60.96% YoY), and the annual figure for FY2025 was -$155000.0, up 60.96%.
  • Change in Receivables for Q4 2025 was -$152000.0 at Sangamo Therapeutics, down from $151000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for SGMO hit a ceiling of $9.9 million in Q3 2024 and a floor of -$10.0 million in Q4 2024.
  • Median Change in Receivables over the past 5 years was -$156000.0 (2025), compared with a mean of -$242650.0.
  • Peak annual rise in Change in Receivables hit 732.33% in 2024, while the deepest fall reached 4331.11% in 2024.
  • Sangamo Therapeutics' Change in Receivables stood at -$2.0 million in 2021, then surged by 56.81% to -$844000.0 in 2022, then soared by 73.34% to -$225000.0 in 2023, then plummeted by 4331.11% to -$10.0 million in 2024, then skyrocketed by 98.48% to -$152000.0 in 2025.
  • The last three reported values for Change in Receivables were -$152000.0 (Q4 2025), $151000.0 (Q3 2025), and $6000.0 (Q2 2025) per Business Quant data.